GlassScriptPhysician profile
Kristen Rice
NPI 1871826115
$9,075.89
in general payments reported to CMS, 2019-2025
33 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $1,369 · 2021: $1,091 · 2022: $1,440 · 2023: $1,149 · 2024: $1,329 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,701 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,700.53 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.17 | 2019-2025 | |
| Allergan, INC. | $964.31 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $764.75 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $718.72 | 2019-2025 | |
| Janssen Biotech, INC. | $693.97 | 2019-2025 | Tremfya |
| Amgen INC. | $650.88 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $530.85 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $398.74 | 2023-2025 | Zoryve |
| Ucb, INC. | $398.04 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $355.63 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Pfizer INC. | $313.66 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $263.89 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Dermavant Sciences, INC. | $215.58 | 2022-2024 | Vtama |
| Leo Pharma INC. | $213.92 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $213.23 | 2019-2025 | Nemluvio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $178.70 | 2019-2025 | Dupixent |
| Vyne Pharmaceuticals INC. | $146.75 | 2020-2021 | |
| Almirall LLC | $145.35 | 2020-2021 | |
| Genzyme Corporation | $138.15 | 2021-2025 | |
| Celgene Corporation | $130.43 | 2019 | |
| Mayne Pharma Commercial LLC | $118.92 | 2019-2024 | |
| Conmed Corporation | $72.86 | 2023 | Visiclear |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.05 | 2022-2024 | Spevigo |
| Dermira, INC. | $39.26 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $35.81 | 2019-2020 | |
| Sandoz INC. | $33.59 | 2020 | |
| Dusa Pharmaceuticals, INC. | $22.72 | 2019 | |
| Organogenesis INC. | $21.84 | 2025 | Cygnus Dual |
| Kyowa Kirin, INC. | $20.65 | 2025 | |
| Incyte Corporation | $16.72 | 2021 | |
| Botanix Sb INC | $14.83 | 2025 | Sofdra |
| Organon LLC | $10.92 | 2025 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.